Neurologic, Electroencephalographic and General Medical Observations in Subjects Administered Ibogaine

Luciano, Daniel J., Della Sera, Edgardo A., Jethmal, Ezequiel G. · 2000 · MAPS Bulletin

AI-extracted · unverified · confirm at source

First human EEG study during ibogaine — all recordings normal. Universal transient cerebellar ataxia resolved by 24h. Movement-induced vomiting (3/5). No withdrawal symptoms at 24h; 2 subjects symptom-free at 1 week.

Dosing: 1 mg/kg test dose + 0.5 mg/kg sensitivity test + ~25 mg/kg treatment dose oral (ibogaine HCl); additional 5 mg/kg oral if early vomiting; rectal re-administration used in 1 subject with persistent vomiting (oral)

Sample size: 5

Contraindications: Seizure disorder, Hypertension, Cardiac disease, Hepatic disease, Renal disease, DSM-4 Axis 1 diagnoses